Evidence map›Paper›PMID 38739263›Full record

ArticleEuropean archives of psychiatry and clinical neuroscience2024

Characterization of cognitive symptoms in post COVID-19 patients.

Michael Ruzicka, Simone Sachenbacher, Fides Heimkes, Aline Olivia Uebleis, Susanne Karch, Fabienne Grosse-Wentrup, Gerardo Jesus Ibarra Fonseca, Nora Wunderlich, Johannes Bogner, Julia Mayerle and 11 more

Abstract read
In one paragraph

Article in European archives of psychiatry and clinical neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Cognition and Long COVID: a Review.Current neurology and neuroscience reports · 2026
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Michael RuzickaDepartment of Medicine III, Ludwig Maximilian University (LMU) University Hospital, LMU Munich, Munich, Germany. michael.ruzicka@med.uni-muenchen.de.ORCID http://orcid.org/0000-0002-2451-1070
Simone SachenbacherDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Fides HeimkesDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Aline Olivia UebleisDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Susanne KarchDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Fabienne Grosse-WentrupDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Gerardo Jesus Ibarra FonsecaDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Nora WunderlichDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Johannes BognerDepartment of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.
Julia MayerleDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Michael von Bergwelt-BaildonDepartment of Medicine III, Ludwig Maximilian University (LMU) University Hospital, LMU Munich, Munich, Germany.
Peter FalkaiDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Marion SubkleweDepartment of Medicine III, Ludwig Maximilian University (LMU) University Hospital, LMU Munich, Munich, Germany.
Thomas RuzickaFaculty of Medicine, Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric University Hospital, University of Zurich, Zurich, Switzerland.
Christopher BeneschDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Elisabeth ValdinociDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Anna PernprunerDepartment of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Anabel ThomasDepartment of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.
Bernhard HeindlStabstelle Strategische Unternehmenssteuerung, LMU Munich, Munich, Germany.
Hans Christian Stubbe *Department of Medicine II, LMU University Hospital, LMU Munich, Munich, Germany.
Kristina Adorjan *Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cognitive symptoms (CS) belong to the most common manifestations of the Post COVID-19 (PC) condition. We sought to objectify CS in PC patients using routine diagnostic assessments: neurocognitive testing (NCT) and brain imaging (BI). Further, we investigated possible associations of CS with patient reported outcomes (PROs), and risk factors for developing CS. Clinical data and PROs of 315 PC patients were assessed at a mean of 6 months after SARS-CoV-2 infection. 231 (73.3%) patients reported any sort of CS. Among them, 78 underwent NCT and 55 received BI. In NCT, the cognitive domains most affected were the working memory, attention, and concentration. Nonetheless, pathological thresholds were exceeded only in few cases. Neurocognitive performance did not differ significantly between patients complaining of severe (n = 26) versus non-severe (n = 52) CS. BI findings were abnormal in 8 (14.5%) cases with CS but were most likely not related to PC. Patients reporting high severity of CS scored worse in the PHQ-9, FSS, WHOQOL-BREF, were more likely to report impaired sleep, and had a higher prevalence of psychiatric diagnoses. Overall, NCT could confirm mild impairment in some but not all PC patients with CS, while BI studies were abnormal in only few cases. CS severity did not affect NCT results, but severe CS were associated with symptoms of depression (PHQ-9), fatigue (FSS), reduced quality of life (WHOQOL-BREF) and higher prevalence of psychiatric illnesses. These findings support the importance of NCT, BI, and neuro-psychological assessment in the work-up of PC patients reporting CS.

trial registrationTrial registration number and date of registration: DRKS00030974, 22 Dec 2022, retrospectively registered.

Indexed as

Cognitive DysfunctionCOVID-19Neuropsychological TestsAdultAgedFemaleHumansMaleMiddle AgedNeuroimagingPatient Reported Outcome MeasuresPost-Acute COVID-19 SyndromeBrain fogCognitive impairmentDepressionFatigueLong COVIDPost COVID-19 syndrome

Identifiers

PMID38739263
PMCPMC11579195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.